Last week, UK-based GW Pharmaceuticals acknowledged that its cannabis-based oral spray, Sativex, failed a late-stage clinical trial as the experimental drug showed no evidence of reducing pain in cancer patients.
Cannabis-based medicine may be on its way to winning the approval of the United States government, but this will likely have no impact of marijuana’s illegal status.
In a time when natural marijuana is considered by the American government to be a gateway to the downtrodden of civil society, it seems odd, but not surprising, that the United States would be champing at the bit to approve cannabis-based medicine.
While most of America is still struggling to legalize marijuana for medicinal purposes, a handful of large pharmaceutical companies are already generating a substantial amount of revenue from prescription drugs based on cannabis medicine.
For the past several months, HIGH TIMES has been providing extensive coverage on GW Pharmaceuticals’ popular cannabis-based drug called Sativex, which in addition to being recognized for years in some countries as a treatment option for multiple scler...